Other clinical trials have identified sotorasib (ClinicalTrials.gov; ID: NCT03600883) [83, 84], JAB-21822 (ClinicalTrials.gov; ID: NCT05009329), and D-1553 (ClinicalTrials.gov; ID: NCT04585035) as targeted treatments for KRAS G12C mutations in solid tumours, non-small cell lung cancer, and colorectal cancer with sotorasib already approved as a treatment for small cell lung cancer. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.